Clinical trials: IGA Glomerulonephritis
IgA Nephropathy
Study of CM313 in Subject With IgA Nephropathy
This study is divided into two parts (Part A and Part B). This study aims to evaluate the safety and efficacy of CM313 in subjects with primary Immunoglobulin A nephropathy(IgAN), while also observing its Pharmacokinetics(PK)…
- Trial name
- NCT06830395
- Testing
- CM313
- Where
- China
- Volunteers
- 106 people
- Sponsor
- Keymed Biosciences Co.Ltd
IGA Glomerulonephritis
Study of Genetic Anomalies of Complement Related Proteins in Patients With IgA Glomerulonephritis
OBJECTIVES: I. Determine whether allelic differences associated with the fourth component of complement, type-1 complement receptor expressed on erythrocytes, and Fc receptor FcgRIII contribute to the pathogenesis of IgA…
- Trial name
- NCT00004305
- Where
- United States
- Volunteers
- 105 people
- Sponsor
- National Center for Research Resources (NCRR)
Primary IgA Nephropathy; Autoimmune Hepatitis
Relative Bioavailability Study of HR19042 in Healthy Subjects
This is a single-center, randomized, open-label, three-period, dual Latin square crossover study. Primary Objective： 1. To evaluate the oral relative bioavailability of HR19042 Capsules compared with budesonide delayed-release…
- Trial name
- NCT06922305
- Testing
- HR19042 Capsule, Tarpeyo®, Budenofalk®
- Where
- China
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Bortezomib, Glomerulonephritis
Bortezomib for Treating Glomerular Diseases
Bortezomib is a proteasome inhibitor that inhibits autoantibody production, and reduces podocyte damage and mesangial hyperplasia caused by NF-κB activation in the kidney.
- Conditions
- Bortezomib, Glomerulonephritis, MN, MPGN
- Trial name
- NCT05383547
- Testing
- Bortezomib
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Ruijin Hospital
IgA Nephropathy
Oxford Classification and Clinical Remission After Initial Treatments in Patients With IgA Nephropathy
IgA nephropathy (IgAN) is the most common form of primary glomerulonephritis and one of the leading causes of end-stage renal disease in China.
- Trial name
- NCT05528991
- Where
- China
- Volunteers
- 474 people
- Sponsor
- Shenzhen Second People's Hospital
IgA Nephropathy
Treatment of Prednisone Plus Cyclophosphamide in Patients With Advanced-stage IgA Nephropathy
Treatment of prednisone plus cyclophosphamide may be superior to treatment of prednisone alone in patients with advanced-stage IgA nephropathy.
- Trial name
- TOPplus-IgAN (NCT01758120)
- Testing
- prednisone plus cyclophosphamide, Prednisone alone
- Where
- China
- Volunteers
- 135 people
- Sponsor
- Guangdong Provincial People's Hospital
IgA Nephropathy at High Risk of Developing ESRD
Treatment Effects of Chinese Medicine (Yi-Qi-Qing-Jie Herbal Compound) Combined With Immunosuppression Therapies in IgA Nephropathy Patients With High-risk of ESRD
The TCM-WINE study is a single-center, prospective, double-blind randomized placebo-controlled trial. Based on optimal supportive care, the trial is aiming to assess superiority with regard to renal protection and reduction of…
- Trial name
- TCMWINE (NCT03418779)
- Testing
- The Yi-Qi-Qing-Jie herbal compound, Immunosuppressants, Optimized Supportive Care
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Guang'anmen Hospital of China Academy of Chinese Medical Sciences
Cancer
Wormwood in Chronic Progressive Disorders With Reduced Appetite
Wormwood is approved herbal medicine for the treatment of reduced appetite in Germany (Registration No.: 1339.99.99). Reduced appetite is observed in many chronic health disorders such as old age, immune disorders and cancer.
- Trial name
- NCT01126931
- Where
- Germany
- Volunteers
- 300 people
- Sponsor
- University Hospital Freiburg
IgA Nephropathy (IgAN), Immunoglobulin A Nephropathy (IgAN)
Mechanistic Evaluation of Atrasentan in Patients With IgA Nephropathy (IgAN)
This multicenter, single-arm, open-label Phase 4 pilot study evaluates the effects of atrasentan added to optimized supportive care on kidney structure and function in adults with biopsy-confirmed IgA nephropathy.
- Trial name
- A-MECH (NCT07820995)
- Testing
- atrasentan
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Illinois Chicago
IgA Nephropathy
Study of Safety and Efficacy of AVB-S6-500 in Patients With IgA Nephropathy
This is an open-label Phase 2a clinical study designed to evaluate the safety and efficacy of AVB-S6-500 in patients with IgA Nephropathy (IgAN). Approximately 24 patients will be enrolled.
- Trial name
- NCT04042623
- Testing
- AVB-S6-500
- Where
- 2 sites in United States, Ukraine
- Volunteers
- 1 people
- Sponsor
- Aravive, Inc.
Diabetic Nephropathies, Primary Focal Segmental Glomerulosclerosis
Study of WAL0921 in Patients With Glomerular Kidney Diseases
This is an adaptive prospective, multi-center, randomized, double-blind, placebo-controlled study to evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamics of WAL0921 in subjects with glomerular kidney disease and…
- Conditions
- Diabetic Nephropathies, Primary Focal Segmental Glomerulosclerosis, Minimal Change Disease, Primary Immunoglobulin A Nephropathy
- Trial name
- NCT06466135
- Testing
- WAL0921
- Where
- 50 sites in United States, Australia and 5 more
- Volunteers
- 96 people
- Sponsor
- Walden Biosciences
Immunoglobulin A Nephropathy (IgAN)
A Study of Cizutamig in Patients With Immunoglobulin A Nephropathy
The purpose of this study is to assess the safety, tolerability, PK, PD, immunogenicity, and preliminary clinical activity of cizutamig in patients with IgAN.
- Trial name
- NCT07135219
- Testing
- Biological: cizutamig
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Peking University First Hospital
Kidney Diseases, Chronic, Glomerular Diseases
Model Development and Application Based on Renal Pathology Images
This single-center retrospective observational cohort study will utilize digital renal pathology images along with corresponding clinical and laboratory data from patients who underwent kidney biopsy at Union Hospital, Tongji…
- Conditions
- Kidney Diseases, Chronic, Glomerular Diseases, Tubulointerstitial Kidney Diseases, IgA Nephropathy (IgAN)
- Trial name
- NCT07816874
- Where
- China
- Volunteers
- 8,000 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Membranous Nephropathy, Lupus Nephritis (LN)
Efficacy and Safety of CD19 CAR-γδ T Cells in the Treatment of Relapsed/Refractory Autoimmune Nephropathy
This study is a single-arm, single-center, open-label, dose-escalation exploratory clinical study designed to evaluate the safety, tolerability, and preliminary efficacy of CD19 CAR-γδ T cells.
- Conditions
- Membranous Nephropathy, Lupus Nephritis (LN), IgA Nephropathy (IgAN)
- Trial name
- NCT07535138
- Testing
- CD19 CAR-γδ T cell
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Air Force Military Medical University, China
IgA Nephropathy
A Controlled Study of Uric Acid on the Progression of IgA Nephropathy
This prospective, randomized controlled study will evaluate the effect of uric acid on the progression of IgA nephropathy.
- Trial name
- NCT00793585
- Testing
- allopurinol, continue their usual therapy
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Sun Yat-sen University
IgA Nephropathy, Chronic Kidney Disease
Steroids and Azathioprine in Advanced IgAN
Some years ago the investigators designed a randomised trial to prospectively evaluate whether adding low-dose azathioprine (1.5 mg/kg/day for six months) to steroids (methylprednisolone 1 g i.v.
- Trial name
- NCT01392833
- Testing
- methylprednisolone, azathioprine, prednisone
- Volunteers
- 46 people
- Sponsor
- A. Manzoni Hospital
IgA Nephropathy
Phase 2b Open-Label Repeat Kidney Biopsy Study
Assess impact of sibeprenlimab on IgA deposition and other histological endpoints in kidney tissue at Week 52 relative to baseline
- Trial name
- NCT06740526
- Testing
- Sibeprenlimab
- Where
- 19 sites in United States, Argentina and 3 more
- Volunteers
- 56 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Glomerulonephritis, IGA
Study of the IgA Repertoire During IgA Deposition Nephropathy.
IgA plays a major role in mucosal and systemic immunity but retains mysterious and ambivalent aspects. They can thus, depending on the situation, prove to be capable of triggering either a protective inflammatory response or, on…
- Trial name
- ERINA (NCT04092491)
- Testing
- blood sample
- Where
- France
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- University Hospital, Limoges
Glomerulonephritis, IGA, Probiotics
Efficacy and Safety of Probiotics Combined With Enteric-coated Budesonide Capsules in Patients With Primary IgA Nephropathy
The goal of this clinical trial is to evaluate the efficacy and safety of probiotics combined with enteric-coated budesonide capsule in patients with IgA nephropathy on the basis of optimized RAS blockade therapy, and to explore…
- Conditions
- Glomerulonephritis, IGA, Probiotics, Budesonide
- Trial name
- NCT06528015
- Testing
- probiotics combined with enteric-coated budesonide capsule
- Where
- China
- Volunteers
- 206 people
- Sponsor
- Gang Xu
IgA Nephropathy
A Randomized, Controlled Clinical Study of Rituximab in Treatment of Primary IgA Nephropathy
A study to evaluate safety and activity in treatment of IgAN patients using Rituximab in combination with RASi(ACEI and/or ARB) compared with RASi.
- Trial name
- NCT05824390
- Testing
- rituximab group
- Where
- China
- Volunteers
- 116 people
- Sponsor
- XIEJINGYUAN